The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Metabolism of Tacrolimus (FK506) and Recent Topics in Clinical Pharmacokinetics
Abstract
Tacrolimus (FK506), an immunosuppressive drug, is co-medicated with multiple drugs under clinical conditions. Tacrolimus is highly lipophilic and is excreted from the body after receiving extensive metabolism. Due to its narrow therapeutic window following organ transplantation, tacrolimus requires therapeutic drug monitoring by an enzyme immunoassay using the monoclonal antibody raised against tacrolimus. Therefore, metabolism studies including drug-drug interaction and metabolite identification studies are essential for the efficient development and clinically optimal usage of this drug. Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily. Metabolic drug-drug interaction studies were conducted to provide information regarding the optimal usage of tacrolimus, and its metabolism was inhibited by known CYP3A inhibitors such as ketoconazole, cyclosporine A, and nifedipine. Recent reports on clinical pharmacokinetics indicate that dose levels of tacrolimus need to be adjusted in transplant patients with CYP3A5 polymorphism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
Staatz, C. E., & Tett, S. E. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443100-00001 · Cited by 913
Clinical Pharmacokinetics of Tacrolimus
Venkataramanan, R., Swaminathan, A., Prasad, T., Jain, A., Zuckerman, S., Warty, V., McMichael, J., Lever, J., Burckart, G., & Starzl, T. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529060-00003 · Cited by 808
Human P-glycoprotein transports cyclosporin A and FK506.
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., & Komano, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53221-x · Cited by 684
Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients
Staatz, C. E., & Tett, S. E. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746010-00002 · Cited by 602
Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00003 · Cited by 323
EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
Dai, Y., Hebert, M. F., Isoherranen, N., Davis, C. L., Marsh, C., Shen, D. D., & Thummel, K. E. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008680 · Cited by 279
Significance of the Minor Cytochrome P450 3A Isoforms
Daly, A. K. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645010-00002 · Cited by 254
Tsuchiya, N., Satoh, S., Tada, H., Li, Z., Ohyama, C., Sato, K., Suzuki, T., Habuchi, T., & Kato, T. (2004) · Transplantation · doi:10.1097/01.tp.0000137789.58694.b4 · Cited by 250
Goto, M., Masuda, S., Kiuchi, T., Ogura, Y., Oike, F., Okuda, M., Tanaka, K., & Inui, K.-I. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114747.08559.49 · Cited by 189
Masuda, S., & Inui, K.-I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.006 · Cited by 184
Zheng, H., Zeevi, A., Schuetz, E. G., Lamba, J. K., McCurry, K. R., Griffith, B. P., Webber, S., Ristich, J., Dauber, J. H., Iacono, A. T., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003262108 · Cited by 149
A highly sensitive method to assay FK-506 levels in plasma.
Tamura, K., Kobayashi, M., Hashimoto, K., et al. (1987) · PubMed · Cited by 148
Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers
Hébert, M. F., Fisher, R. M., Marsh, C. L., et al. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007499 · Cited by 144
Shiraga, T., MATSUDA, H., Nagase, K., Iwasaki, K., Kosei, N. O. D. A., Yamazaki, H., Shimada, T., & Funae, Y. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90136-8 · Cited by 127
Self-citationIwasaki, K., Shiraga, T., Nagase, K., Tozuka, Z., Kosei, N. O. D. A., Sakuma, S., FUJITSU, T., Shimatani, K., Sato, A., & Fujioka, M. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08219-4 · Cited by 106
Self-citationVincent, S. H., Karanam, B. V., Painter, S. K., & Chiu, S. L. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90711-5 · Cited by 105
den Buijsch, R. A. M. O., Christiaans, M. H. L., Stolk, L. M., de Vries, J. E., Cheung, C. Y., Undre, N. A., van Hooff, J. P., van Dieijen‐Visser, M. P., & Bekers, O. (2007) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00504.x · Cited by 100
The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy
Tsunoda, S. M., & Aweeka, F. T. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630020-00003 · Cited by 64
Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes.
Iwasaki, K., Matsuda, H., Nagase, K., Shiraga, T., Tokuma, Y., & Uchida, K. (1993) · PubMed · Cited by 59
Self-citation
Cited by
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, M., van Gelder, T., Åsberg, A., Haufroid, V., Hesselink, D. A., Langman, L., Lemaitre, F., Marquet, P., Seger, C., Shipkova, M., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000640 · Cited by 707
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317550-000000000-00000 · Cited by 343
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317350-000000000-00000 · Cited by 336
PharmGKB summary: cyclosporine and tacrolimus pathways
Barbarino, J. M., Staatz, C. E., Venkataramanan, R., Klein, T. E., & Altman, R. B. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328364db84 · Cited by 257
Jang, H. Y., Song, J., Kim, J. H., Lee, H., Kim, I.-W., Moon, B., & Oh, J. M. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00639-0 · Cited by 63
Metadata
- Authors
- Iwasaki, K.
- Venue
- Drug Metabolism and Pharmacokinetics
- Published
- 2007
- Volume
- 22
- Issue
- 5
- Pages
- 328-335
- ISSN
- 1347-4367 (ISSN-L)
- OpenAlex
- W1990267967
- Cited by
- 264
- References
- 19
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.